🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07220330
Enrolling by invitation Observational

An Investigational Study Examining the Cross-Validation of QbMobile in ADHD and Normative Populations

NCT07220330 · tracked via the Priya Life Science USA tracker
Sponsor
Qbtech AB
Phase
Observational
Started
2025-01-15
Last updated
2026-05-06

Condition(s) studied

No History of ADHDAttention Deficit Hyperactivity Disorder (ADHD)Healthy Volunteer

Investigational drug(s) / intervention(s)

QbMobile

QbMobile: QbMobile is a software application that can be installed on a smartphone device used to measure activity, attention, impulsivity, and movement patterns in participants over a two-day period.

Study summary

The purpose of this study is to investigate QbMobile ability to collect and provide accurate and objective data which can be used to facilitate assessment and treatment procedures for ADHD in a clinical setting as well as remotely.

Eligibility

Sex
ALL
Min age
6 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Provide written informed consent (including parent/legal guardians consent when this is required for individuals under 18 years old and assent as is required based on the age of participant) for QbMobile; * Aged \> 6 years and \< 60 years old; * Have no documented or suspected current or lifetime diagnosis of ADHD or referred for an initial assessment for ADHD or have a diagnosis of ADHD but not currently receiving treatment; * Meet DSM-5 or ICD-11 criteria for a primary diagnosis of ADHD (combined, inattentive, or hyperactivity/impulsive presentation) per sites standard clinical care evaluation; * Qbtech Rating Scale total score of \>24 at Visit 1; * Have adequate sensory and physical ability to complete QbMobile; * Possess or has access to an iPhone model that supports QbMobile. Exclusion Criteria: * Intellectual disability designated by IQ\<75; * Has used psychostimulant medication within the past 7 days prior to Visit 1; * A current medical diagnosis that could significantly affect test performance (brain injuries, Parkinson's disease, current epilepsy or active seizures, amyotrophic lateral sclerosis (ALS), multiple sclerosis, dementias (e.g., vascular dementia, Alzheimer disease, etc.); * Other conditions that could affect test performance (migraine or other types of severe headache, chronic or acute pain); * Substance use (e.g., alcohol, drugs) that may affect performance on the day of the tests.

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Prodigy Psychiatric Group San Jose California
Bokhari Medical Consortium Largo Florida
Nona Pediatric Center Orlando Florida

More Qbtech AB trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07220330 on ClinicalTrials.gov ↗ ← All trials in the USA